Zhan-Hong Chen
Overview
Explore the profile of Zhan-Hong Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian T, Chen Z, Zheng Z, Liu Y, Zhao Q, Liu Y, et al.
Theranostics
. 2025 Feb;
15(5):2085.
PMID: 39897546
[This corrects the article DOI: 10.7150/thno.43427.].
2.
Wang R, Zhu Q, Ye W, Huang Y, Chen Z, Zheng Y, et al.
Discov Med
. 2024 Mar;
36(182):527-537.
PMID: 38531793
Background: The clinical outcomes of chemotherapy (CT) for the treatment of metastatic triple-negative (TN) and hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) have proven...
3.
Huang P, Huang J, Zheng Y, Cao W, Shao X, Chen J, et al.
Front Pharmacol
. 2022 Aug;
13:883600.
PMID: 35991878
Cardiotoxicity associated with the sequential use of anthracyclines followed by trastuzumab is common in adjuvant therapy of patients with HER2-positive early breast cancer (eBC). However, the cardiac safety of trastuzumab...
4.
Qi J, Cui D, Wu Q, Zhao Q, Chen Z, Li L, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35805009
Metastasis is the main cause of death for patients suffering gastric cancer. Epithelial-mesenchymal transition (EMT) and cancer stem cells (CSC) are critical attributes of metastasis, both of which are regulated...
5.
Shen X, Li G, Zheng Y, Chen Z, Cao W, Wang X, et al.
Ann Transl Med
. 2021 Sep;
9(16):1334.
PMID: 34532471
Background: Everolimus (EVE) is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, and it is approved for the treatment of advanced breast cancer (ABC). However, there is still...
6.
Liu M, Chen Z, Zhao L, Zhao J, Rong D, Ma X, et al.
Oncol Res Treat
. 2021 Aug;
44(9):450-468.
PMID: 34380137
Introduction: The prognosis of advanced hepatocellular carcinoma (HCC) varies in patients receiving transcatheter arterial chemoembolization (TACE). In this study, we aimed to assess the prognostic value of serum apolipoprotein B...
7.
Wang T, Hong Y, Chen Z, Wu D, Li Y, Wu X, et al.
Biochem Biophys Res Commun
. 2021 Apr;
558:14-21.
PMID: 33894673
Sorafenib remains the standard first-line treatment for advanced hepatocellular carcinoma (HCC), although other clinical trials are currently underway for treatments that show better curative effects. However, some patients are not...
8.
Zeng Z, Lu J, Wang Y, Sheng H, Wang Y, Chen Z, et al.
Cancer Med
. 2021 Mar;
10(7):2423-2441.
PMID: 33666372
Background: Numerous reports on microRNAs have illustrated their role in tumor growth and metastasis. Recently, a new prognostic factor, miR-125b-2-3p, has been identified for predicting chemotherapeutic sensitivity in advanced colorectal...
9.
Hu P, Li T, Lin J, Qiu M, Wang D, Liu Z, et al.
Signal Transduct Target Ther
. 2020 Sep;
5(1):183.
PMID: 32900990
The acidic tumor microenvironment provides an energy source driving malignant tumor progression. Adaptation of cells to an acidic environment leads to the emergence of cancer stem cells. The expression of...
10.
Huang J, Huang P, Shao X, Sun Y, Lei L, Lou C, et al.
Medicine (Baltimore)
. 2020 Jul;
99(29):e20821.
PMID: 32702824
This study was to investigate the efficacy and safety of fulvestrant 500 mg for the treatment of hormone receptor positive advanced postmenopausal women, including ovarian ablation and investigated factors associated...